XALKORI 250 mg, hard capsule 60 capsules
Active ingredients: Crizotinib
Commercialized according to BDPMDispensing in France: Prescription only
Hard capsule60 capsulesorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- XALKORI 250 mg, gélule
- Pharmaceutical form
- gélule
- Route of administration
- orale
- Presentation description
- 6 plaquette(s) thermoformée(s) PVC-Aluminium de 10 gélule(s)
- Marketing authorisation holder
- PFIZER EUROPE MA EEIG (BELGIQUE)
- Reimbursement according to BDPM
- 100%
- Reimbursement conditions
- Ce médicament peut être pris en charge ou remboursé par l'Assurance Maladie dans les cas suivants :<br><br>- Cancer du poumon non à petites cellules, mais pour certaines formes et dans certaines conditions uniquement ; JOURNAL OFFICIEL ; 03/09/13
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 16 Jan 2013
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
61506083CIP72676279CIP133400926762797Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| CRIZOTINIBgélule | 250 mg · une gélule | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.